Saltar para: Post [1], Pesquisa e Arquivos [2]

Noticias de Crohn - Copy.png

Resumo na língua original:

Celgene Corporation is giving up on GED-0301 as a Crohn’s disease therapy, but will continue to evaluate its ability to treat ulcerative colitis.


It ended its Phase 3 REVOLVE clinical trial (NCT02596893) and its SUSTAIN extension trial (NCT02641392) of GED-0301 as a potential Crohn’s treatment after an independent trial monitoring board recommended the discontinuations. The board had reviewed the therapy’s benefits and risks, and the implication of its recommendation was that GED-0301 failed to generate enough benefits.





Ler artigo original


Autoria e outros dados (tags, etc)

publicado às 11:00


  Pesquisar no Blog

Subscrever por e-mail

A subscrição é anónima e gera, no máximo, um e-mail por dia.